ANTIHYPERTENSIVE CARDIOVASCULAR PHARMACEUTICAL PREPARATIONS

Brand Owner (click to sort) Address Description
ADROLEX Merrell Dow Pharmaceuticals Inc. Cincinnati OH Antihypertensive and Cardiovascular Pharmaceutical Preparations;
DYNATROP Merrell Dow Pharmaceuticals Inc. Cincinnati OH Antihypertensive and Cardiovascular Pharmaceutical Preparations;
LOXACOR Merrell Dow Pharmaceuticals Inc. Cincinnati OH Antihypertensive and Cardiovascular Pharmaceutical Preparations;
PERFAN Merrell Dow Pharmaceuticals Inc. Cincinnati OH Antihypertensive and Cardiovascular Pharmaceutical Preparations;
PERFAN Merrell Dow Pharmaceuticals Inc. Cincinnati OH antihypertensive and cardiovascular pharmaceutical preparations;PER-FAN;
PERVAS Merrell Dow Pharmaceuticals Inc. Cincinnati OH ANTIHYPERTENSIVE AND CARDIOVASCULAR PHARMACEUTICAL PREPARATIONS;
REDALEX Merrell Dow Pharmaceuticals Inc. Cincinnati OH ANTIHYPERTENSIVE AND CARDIOVASCULAR PHARMACEUTICAL PREPARATIONS;
TROVADYN Merrell Dow Pharmaceuticals Inc. Cincinnati OH ANTIHYPERTENSIVE AND CARDIOVASCULAR PHARMACEUTICAL PREPARATIONS;
VOLCARD Merrell Dow Pharmaceuticals Inc. Cincinnati OH ANTIHYPERTENSIVE AND CARDIOVASCULAR PHARMACEUTICAL PREPARATIONS;
VOLDYN Merrell Dow Pharmaceuticals Inc. Cincinnati OH ANTIHYPERTENSIVE AND CARDIOVASCULAR PHARMACEUTICAL PREPARATIONS;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. Methods of using a genetic polymorphic variation in the human beta-1 adrenergic receptor gene as a drug response marker are presented. Determining the presence or absence of the A145G genetic variation in the human beta-1 adrenergic receptor gene is useful in predicting an individual's relative response to different antihypertensive drugs; optimizing antihypertensive treatment for an individual; selecting candidate human subjects for participation in clinical trials involving antihypertensive drugs; and, predicting the relative responses among a plurality of individuals to an antihypertensive drug.